BSc (Xiamen U); MS, PhD (Peking Union Medical College); PhD (Karolinska Institutet)
Chui Fook-Chuen Professor in Molecular Medicine
L3-71, Laboratory Block,
21 Sassoon Road, Hong Kong
T +852 3917 9542
F +852 2855 1254
zhongjun@hku.hk
Zhongjun Zhou is currently the Chui Fook-Chuen Endowed Professor in Molecular Medicine at the School of Biomedical Sciences, The University of Hong Kong. He obtained a BSc degree in Biochemistry from Xiamen University, Master of Science in Biochemistry and MD in Pathophysiology from Peking Union Medical College (PUMC & CAMS). After 2 years in Peking University Health Center, he left for Karolinska Hospital in Stockholm, Sweden, supported by Swedish Cancer Foundation. He then received a PhD degree in Medical Biochemistry from Karolinska Institute. In Dec 2002, he joined the department of Biochemistry as a Research Assistant Professor and was promoted to Associate Professor three years later. He has published over 90 original papers, reviews and book chapter. He is the co-founding Chair of Asian Association of Ageing Research and the elected Inaugural President of Hong Kong Society for Cell Biology (HKSCB). He is the council member of Chinese Society of Cell Biology, Scientific Advisory Board member of American Federation of Aging Research, and Distinguished Visiting Professor of The Macau University.
Well recognized internationally in the field of matrix biology and ageing, Prof Zhou is interested in understanding the biological functions of extracellular and nuclear matrix proteins. His works focus on signalling regulation in development, ageing, and tumorigenesis using genetically modified mice and human patient tissues. He identified lamin A as the endogenous substrate of metalloproteinase Zmpste24 and demonstrated for the first time that genomic instability is behind the most severe human early ageing disorder, Hutchinson-Gilford Progeria Syndrome (HGPS). He established the first HGPS animal model in the world and has demonstrated that nuclear matrix is not simply a scaffold but also a functional structure regulating chromatin dynamics through modulating epigenetic factors, such as histone deacetylases and acetyltransferases. His group is the first to show epigenetic contribution to premature ageing. Prof Zhou’s works have revealed several critical pathways regulating ageing and longevity, especially the interplay between SIRT6 and p53, achieving the longest lifespan extension in mammals by 14-fold in Sirt6 deficient mice. His group demonstrated the critical role for lamin A in maintaining SIRT1/6 activities that decline with age. The works on health span extension provide new hope for patients with HGPS and other ageing-associated diseases. He has also made outstanding contributions to the understanding of membrane-type 1 matrix metalloproteinase (MT1-MMP) in development, metabolism, regeneration, ageing and in various pathological conditions. He demonstrated that MT1-MMP is the major negative Notch signalling regulator to maintain lymphocyte differentiation. In addition, he beautifully showed the cross-talk between ADAM and MMP in regulating FGFR2 signalling and osteogenesis. His group showed that MT1-MMP is an endogenous inhibitor of lymph angiogenesis and regulates body-weight, Osteognesis, adipogenesis, and ageing, revealing a critical role for MT1-MMP in insulin resistance and food in-take through cleavage of various receptors. His group also showed that Isthmin-1 (Ism1) plays a critical role in regulating renal branching morphogenesis, mammary gland development and hematopoiesis. Recently, his team has developed a platform to generate human islet organoids and identified over hundreds of senescent antigens for the development of anti-ageing vaccine and antibody drugs. In the past few years, his team also established novel strategy for single cell OMICs analysis (Indexed Tagmentation sc-OMICs) with higher through-put and resolution. This platform enables a better, faster and cheaper single cell analysis.
Prof Zhou has established a close collaboration with clinicians and has identified several disease genes, such as familial hypertension. Inflammatory bowel diseases, and precocious sexual maturation. With the disease models established in his group, he aims to investigate the molecular mechanisms underlying these diseases caused by specific mutations. In addition, the clinical intervention and drugs for therapies will be developed.
Several postdoctoral positions are available for self-motivated fresh graduates. The candidates are expected to have experiences either in modern molecular biology especially single cell OMICs or strong background in Immunology, Inflammation and hand-on experiences of vaccine development. Candidate with experiences of human organoid will be highly appreciated.
A. Human Islet Organoid for Diabetes Treatment
B. Single Cell OMICs Technology Development
C. Sirtuins
D. Ageing and Premature ageing
E. Development and Diseases
F. Invited Reviews
Chui Fook-Chuen Endowed Professor in Molecular Medicine, 2025, HKU
2025
Torch Scholar, 2024, Ministry of Science & Technology of CHINA
2024
Croucher Senior Research Fellow, 2015/2016, Croucher Foundation
2015/2016
Outstanding Research Award, 2014/2015, The University of Hong Kong
2014/2015
State Science and Technology Award (2nd Class), 2011, State Council, China
2011
International Society of Matrix Biology Nominated Speaker, 2007, Cains, Australia
2007
Outstanding Research Output Award, 2006, Faculty of Medicine, The University of Hong Kong
2006
Distinguished Overseas Young Chinese Scientist Award, 2005, Natural Science Foundation of China
2005
Young Investigator Award, 2000, International Society of Fibrinolysis and Proteolysis, Japan
2000
Swedish Cancer Foundation Fellow, 1996-1997, Swedish Cancer Fond, Sweden
Postdoctoral Fellows:
Postgraduate Students:
Visiting Scholar:
Research Assistant:
Postdoctoral Positions available in the areas of stem cells, development and ageing
Several positions for postdoctoral fellow or senior research assistants are available immediately. The positions are initially for two years with possibility of renewal subject to satisfactory performance.
Applicants should possess either PhD in biomedical sciences or MD degree. Candidates with background of developmental biology, stem cells, organoid, regenerative medicine, cardiac damage and repair, functional genomics, bioinformatics, or single cell omics are strongly encouraged to apply. The appointees are expected to work independently as well as collaboratively with a group of scientists in Universities, Research Institutes and Industries to develop new strategies to fight against degenerative diseases as well as cancer.
Enquiries about the posts should be sent to zhongjun@hku.hk.
A highly competitive salary commensurate with qualifications and experiences will be offered, in addition to annual leave and medical benefits. Candidate should sent their application together with updated CV to zhongjun@hku.hk.
Last Update : 2025-12-10